Antibodies against β2-glycoprotein I (anti-β2GPI) are one of the hallmarks of the antiphospholipid syndrome (APS). However, they are heterogenic regarding their epitope specificity, pathogenic mechanisms and their avidity. In the current study we present some outstanding issues about avidity of anti-β2GPI antibodies. Our results confirmed that high avidity anti-β2GPI are associated with thrombosis and APS, while in low avidity anti-β2GPI group non-APS (predominantly systemic lupus erythematosus) patients prevailed.
GharaviAEReiberH. Affinity and avidity of autoantibodies. In: PeterJBShoenfeldY (eds). Autoantibodies. Amsterdam: Elsevier, 1996. 13–23.
2.
ReddelSWKrilisSA. Testing for and clinical significance of anticardiolipin antibodies. Clin Diagn Lab Immunol1999; 6: 775–782.
3.
BožičBČučnikSKvederTRozmanB. Avidity of anti-beta-2-glycoprotein I antibodies. Autoimmun Rev2005; 4: 303–308.
4.
ČučnikSKvederTUlcova GallovaZ. The avidity of anti-β2-glycoprotein I antibodies in patients with or without APS: a collaborative study in the frame of the European forum on antiphospholipid antibodies. Lupus2011; 20: 1166–1171.
5.
ČučnikSKvederTKrižajIRozmanBBožičB. High avidity anti-β2-glycoprotein I antibodies in patients with antiphospholipid syndrome. Ann Rheum Dis2004; 63: 1478–1482.
6.
MiyakisSLockshinMDAtsumiT. International consensus statement on an update of classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost2006; 4: 295–306.
7.
HochbergMC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1997; 40: 1725–1725.
8.
De LaatBDerksenRHWMde GrootPG. High-avidity anti-β2 glycoprotein I antibodies highly correlate with thrombosis in contrast to low-avidity anti-β2 glycoprotein I antibodies. J Thromb Haemost2006; 4: 1619–1621.
